Pacific Biosciences of California (PACB) stock price, revenue, and financials

Pacific Biosciences of California market cap is $5.9 b, and annual revenue was $78.89 m in FY 2020

$5.9 B

PACB Mkt cap, 12-Nov-2021

$78.9 M

Pacific Biosciences of California Revenue FY, 2020
Pacific Biosciences of California Gross profit (FY, 2020)32.6 M
Pacific Biosciences of California Gross profit margin (FY, 2020), %41.3%
Pacific Biosciences of California Net income (FY, 2020)29.4 M
Pacific Biosciences of California EBIT (FY, 2020)-104.4 M
Pacific Biosciences of California Cash, 31-Dec-202081.6 M
Pacific Biosciences of California EV5.9 B
Get notified regarding key financial metrics and revenue changes at Pacific Biosciences of CaliforniaLearn more
Banner background

Pacific Biosciences of California Revenue

Pacific Biosciences of California revenue was $78.89 m in FY, 2020

Embed Graph

Pacific Biosciences of California Revenue Breakdown

Embed Graph

Pacific Biosciences of California revenue breakdown by geographic segment: 56.0% from North America, 22.1% from Europe and 21.9% from Asia

Pacific Biosciences of California Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

10.6m10.5m10.0m7.3m2.8m5.6m6.0m7.4m11.6m11.4m20.6m17.6m24.9m13.9m19.1m20.7m25.1m24.9m20.1m23.5m19.4m21.6m18.2m16.4m24.6m21.9m15.6m17.1m19.1m

Cost of goods sold

2.7m7.2m10.2m7.0m2.6m4.6m5.0m6.2m9.0m8.3m7.5m11.7m10.4m7.4m9.6m10.1m12.5m16.0m12.1m15.3m12.1m12.7m15.0m11.3m15.0m15.0m8.1m10.5m12.0m

Gross profit

7.9m3.3m(152.0k)275.0k190.0k930.0k1.1m1.2m2.7m3.1m13.2m5.9m14.5m6.6m9.5m10.6m12.6m8.9m8.0m8.2m7.3m8.9m3.2m5.1m9.6m6.9m7.5m6.6m7.1m

Gross profit Margin, %

74%32%(2%)4%7%17%18%17%23%27%64%34%58%47%50%51%50%36%40%35%38%41%18%31%39%32%48%39%37%

R&D expense

19.5m20.0m12.1m11.3m12.6m12.0m11.7m10.4m11.8m12.4m11.7m14.5m15.0m16.2m16.4m17.5m17.5m17.0m16.9m15.8m16.3m15.7m14.4m15.5m14.9m15.0m15.3m15.0m16.5m

General and administrative expense

11.0m12.8m15.3m11.6m10.1m9.6m9.4m10.8m9.2m9.0m9.9m10.8m10.8m10.8m11.7m11.2m11.9m15.3m15.5m14.0m14.9m14.9m13.5m19.8m19.1m20.1m24.9m15.1m14.8m

Operating expense total

30.6m32.8m27.4m22.8m22.8m21.5m21.1m21.2m20.9m21.4m21.6m25.3m25.9m3.9m28.1m28.7m29.4m32.2m32.4m29.8m31.2m30.6m27.9m35.3m34.0m35.0m40.2m30.1m31.2m

EBIT

(22.7m)(29.4m)(27.5m)(22.6m)(22.6m)(20.6m)(20.0m)(19.9m)(18.2m)(18.3m)(8.4m)(19.3m)(11.4m)2.6m(18.6m)(18.1m)(16.7m)(23.3m)(24.4m)(21.6m)(23.9m)(21.7m)(24.7m)(30.1m)(24.4m)(28.1m)(32.7m)(23.5m)(24.2m)

EBIT margin, %

(213%)(280%)(274%)(309%)(813%)(369%)(331%)(269%)(157%)(160%)(41%)(110%)(46%)19%(97%)(87%)(67%)(94%)(121%)(92%)(124%)(101%)(136%)(183%)(99%)(128%)(210%)(138%)(127%)

Interest expense

359.0k673.0k821.0k

Net Income

(22.5m)(29.3m)(27.6m)(22.5m)(22.7m)(21.1m)(20.5m)(20.5m)(18.9m)(19.1m)(9.2m)(20.2m)(11.9m)1.8m(19.4m)(18.5m)(17.5m)(23.9m)(25.5m)(22.0m)(24.2m)(22.5m)(25.0m)(30.3m)(24.6m)(29.1m)1.3m(23.1m)(23.7m)

Pacific Biosciences of California Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

54.5m57.6m56.3m33.6m32.6m53.0m40.8m64.8m41.3m28.2m35.4m30.3m25.9m27.2m20.1m24.8m22.8m29.0m36.5m25.9m25.5m23.1m38.1m38.2m30.4m33.1m68.9m43.3m69.0m

Accounts Receivable

5.4m4.4m1.5m3.4m532.0k2.0m4.1m3.8m3.4m4.3m2.4m5.3m4.0m4.2m8.0m10.4m11.8m10.4m9.5m8.9m8.5m7.4m6.4m7.3m12.1m10.0m7.3m11.3m11.8m

Prepaid Expenses

3.2m1.9m2.1m1.9m2.2m1.6m759.0k1.2m1.6m1.2m1.1m1.6m1.6m11.5m7.4m11.0m6.9m6.5m3.5m2.5m2.1m2.0m2.0m2.8m2.5m2.7m3.5m2.9m3.2m

Inventories

19.6m20.3m11.8m10.3m10.2m10.6m10.3m9.8m8.3m9.4m11.4m13.5m12.0m11.6m12.2m14.2m16.5m15.3m17.3m18.2m25.9m23.4m19.7m19.7m17.4m15.1m16.1m16.8m15.9m

Current Assets

244.7m220.3m176.8m152.6m132.3m126.5m122.1m141.8m132.1m119.9m114.1m99.5m90.2m86.2m119.1m138.1m122.5m88.3m132.9m113.6m115.7m96.4m143.9m112.6m98.9m76.9m169.5m150.9m239.5m

PP&E

16.2m17.4m17.6m16.9m15.5m12.8m11.7m10.5m8.5m7.9m7.0m6.7m6.4m7.9m9.1m11.2m14.0m42.4m40.3m39.6m36.7m36.1m34.5m33.6m33.5m31.6m29.1m27.7m26.6m

Total Assets

261.2m238.0m194.7m169.9m148.2m139.8m134.3m152.8m141.0m128.2m121.6m106.4m96.8m99.8m140.2m161.4m150.6m135.5m177.9m157.9m156.9m137.1m182.9m185.6m170.6m146.1m234.8m213.6m300.3m

Accounts Payable

9.0m8.2m4.3m4.1m2.9m3.0m2.6m3.4m3.9m5.4m5.8m6.9m5.8m6.1m4.7m5.4m8.3m8.2m6.5m8.6m8.6m4.2m6.0m8.7m8.0m8.1m4.2m7.4m5.4m

Short-term debt

125.0k132.0k148.0k156.0k165.0k182.0k3.1m2.6m2.9m14.9m15.2m15.5m4.0m4.1m4.2m

Current Liabilities

21.5m21.1m19.8m14.9m13.6m13.6m15.1m22.5m22.5m28.0m29.1m38.4m39.0m38.8m32.0m33.8m32.1m35.4m35.7m30.3m24.9m22.3m21.6m45.1m49.5m50.7m132.0m130.9m130.3m

Long-term debt

2.9m2.8m2.7m2.7m2.7m2.6m13.0m13.2m13.5m13.7m13.9m14.3m14.6m14.8m15.2m15.5m15.8m13.3m10.4m10.5m13.9m14.1m14.4m59.8m59.2m58.5m40.9m39.9m38.8m

Total Debt

3.0m3.0m2.9m2.9m2.8m2.7m13.0m26.3m27.1m27.4m27.8m28.7m29.1m29.6m30.4m31.0m31.6m16.4m13.1m13.4m13.9m14.1m14.4m74.7m74.4m74.1m44.9m44.0m43.0m

Total Liabilities

27.9m27.3m26.8m21.7m19.7m32.7m33.9m69.3m65.5m69.2m68.6m65.9m62.9m58.4m51.4m53.3m52.0m66.3m62.0m56.5m54.2m51.6m51.0m90.7m94.8m95.1m174.4m172.3m170.8m

Common Stock

54.0k55.0k55.6m639.8m642.8m664.2m65.2k66.1m70.0k71.0k71.0k75.0k75.0k76.0k87.0k91.0k93.0k94.0k116.0k116.0k132.0k132.0k149.0k153.0k153.0k153.0k154.0k154.0k180.0k

Additional Paid-in Capital

622.5m629.4m678.0m681.6m709.6m712.2m715.4m742.0m747.3m753.0m821.2m858.9m867.1m880.5m952.7m960.3m1.0b1.0b1.1b1.1b1.1b1.1b1.1b1.1b1.2b

Retained Earnings

(389.5m)(418.7m)(469.1m)(491.6m)(514.4m)(557.1m)(577.6m)(598.1m)(634.2m)(653.3m)(662.5m)(701.6m)(713.6m)(711.8m)(732.5m)(751.0m)(768.5m)(811.4m)(836.9m)(859.0m)(903.7m)(926.3m)(951.3m)(1.0b)(1.0b)(1.1b)(1.1b)(1.1b)(1.1b)

Total Equity

233.3m210.7m167.9m148.2m128.5m107.1m100.4m83.5m75.5m59.0m53.0m40.5m33.8m41.4m88.8m108.1m98.7m69.2m115.9m101.4m102.7m85.5m131.9m94.9m75.8m51.0m60.4m41.4m129.5m

Debt to Equity Ratio

0.3 x0.4 x0.5 x0.5 x0.7 x0.9 x0.7 x0.3 x0.3 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x0.3 x0.3 x0.3 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.2 x1.1 x1.2 x1.3 x1.3 x1.8 x1.9 x2.2 x2.3 x2.6 x2.9 x2.4 x1.6 x1.5 x1.5 x2 x1.5 x1.6 x1.5 x1.6 x1.4 x2 x2.3 x2.9 x3.9 x5.2 x2.3 x

Pacific Biosciences of California Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(57.3m)(86.6m)(27.6m)(50.1m)(72.8m)(21.1m)(41.6m)(62.1m)(18.9m)(38.0m)(47.2m)(20.2m)(32.1m)(30.3m)(19.4m)(37.9m)(55.3m)(23.9m)(49.4m)(71.4m)(24.2m)(46.7m)(71.8m)(30.3m)(54.9m)(84.0m)1.3m(21.8m)(45.5m)

Depreciation and Amortization

2.9m4.3m1.6m3.4m5.0m1.5m2.9m4.2m1.2m2.3m3.3m908.0k1.8m2.7m848.0k1.8m2.8m2.9m4.8m6.6m1.8m3.6m5.4m1.8m3.6m5.5m1.7m3.2m4.8m

Accounts Receivable

(5.1m)(4.1m)3.1m1.2m4.0m813.0k(1.3m)(992.0k)(637.0k)(1.5m)376.0k(1.9m)(544.0k)(758.0k)(2.9m)(5.2m)(6.5m)980.0k1.9m2.5m5.0m6.0m7.0m1.3m(3.5m)(1.4m)7.9m3.9m3.4m

Inventories

(13.8m)(15.1m)3.1m4.1m4.2m(607.0k)(293.0k)171.0k1.7m610.0k(1.3m)(2.1m)(643.0k)(2.0m)(2.1m)(4.5m)(7.1m)(149.0k)(2.2m)(4.0m)(2.7m)(560.0k)3.0m(1.9m)(40.0k)2.3m(3.4m)(3.8m)(3.0m)

Accounts Payable

(483.0k)(1.2m)(492.0k)(681.0k)(1.8m)22.0k(384.0k)425.0k2.2m3.7m4.1m983.0k203.0k364.0k(39.0k)683.0k2.4m(89.0k)(1.9m)432.0k(942.0k)(4.8m)(2.9m)2.1m685.0k1.5m(4.1m)(1.0m)(3.0m)

Cash From Operating Activities

(64.4m)(88.2m)(17.3m)(40.9m)(58.6m)(17.6m)(34.0m)(15.3m)(16.3m)(29.9m)(36.1m)(23.9m)(31.4m)(47.2m)(20.3m)(39.2m)(55.0m)(16.7m)(29.5m)(47.3m)(18.8m)(33.3m)(47.4m)(25.3m)(42.9m)(60.1m)75.4m51.6m33.8m

Purchases of PP&E

(5.6m)(7.8m)(274.0k)(781.0k)(1.3m)(297.0k)(577.0k)(807.0k)(477.0k)(942.0k)(1.1m)(717.0k)(1.7m)(2.1m)(457.0k)(3.3m)(5.6m)(2.7m)(6.1m)(9.4m)(344.0k)(1.7m)(1.8m)(1.3m)(1.9m)(2.7m)(117.0k)(436.0k)(972.0k)

Cash From Investing Activities

(32.4m)(9.4m)13.0m13.7m29.6m(5.6m)(12.7m)(9.0m)8.2m8.4m21.1m15.3m16.5m31.0m(23.2m)(32.4m)(21.5m)25.5m(17.1m)(12.2m)(7.7m)4.4m(32.9m)38.0m45.8m65.5m(54.3m)(57.2m)(120.8m)

Short-term Borrowings

(4.5m)(4.5m)(16.0m)(16.0m)(16.0m)

Cash From Financing Activities

3.7m7.5m1.8m2.0m2.7m29.7m41.0m42.5m23.0m23.3m24.1m2.4m4.4m6.9m30.0m62.7m65.7m3.4m66.3m68.7m35.5m35.4m101.9m6.7m8.1m8.4m18.2m18.8m126.0m

Net Change in Cash

(93.1m)(90.1m)(2.6m)(25.2m)(26.3m)6.5m(5.7m)18.2m14.9m1.8m9.0m(6.2m)(10.5m)(9.2m)(13.5m)(8.9m)(10.8m)12.2m19.7m9.2m9.0m6.6m21.6m19.4m11.0m13.7m39.2m13.2m38.9m

Pacific Biosciences of California Ratios

USDQ2, 2011

Financial Leverage

1.1 x

Pacific Biosciences of California Operating Metrics

FY, 2016

Patents (Foreign)

133

Patents (US)

221

Patents Pending

187